



Klaria reschedules quarterly report date

Klaria Pharma Holding (publ) announces that the quarterly report for Q2 2026 will be published on August 31.

Klaria Pharma Holding (publ) announces that the quarterly report for Q2 2026 will be published on August 31. The previously announced date was the 27th of August.

For more information, visit the Klaria Pharma Holding website klaria.com or contact:

Fredrik Hübinette, Chairman of the Board of Directors

info@[klaria.com](mailto:info@klaria.com)

Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.